Navigation Links
Kensey Nash Announces 400,000 Share Stock Repurchase Program
Date:12/10/2009

EXTON, Pa., Dec. 10 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that its board of directors has approved a stock repurchase. The new program allows the Company to repurchase up to a total of 400,000 of its issued and outstanding shares of Common Stock and has no scheduled expiration. The Company intends to finance the repurchases using its available cash.

Kensey Nash Corporation plans to repurchase its shares for cash, from time to time in the open market, through block trades or otherwise. The repurchase program does not require the Company to purchase any specific dollar value or number of shares. Any purchases under the program will depend on market conditions and may be commenced or suspended at any time or from time to time without prior notice. As of November 30, 2009, the Company had approximately 11,008,568 shares of Common Stock outstanding.

About Kensey Nash Corporation. Kensey Nash Corporation is a leader in developing, manufacturing and processing resorbable biomaterial products, incorporating its proprietary collagen and synthetic polymer technology. This expertise is used to develop and commercialize its products through strategic partners. The company has an extensive range of products, which are sold in multiple medical markets, including, the cardiology, orthopedic, sports medicine, spine, endovascular and general surgery markets. The company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements. This press release as well as other Company press releases contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward-looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, current economic conditions, foreign currency fluctuations, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some of the associated milestone payments will not be received), Spectranetics' success in selling the ThromCat(TM) product, the Company's success in distributing its products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, the Company's success in its research and development efforts in its cartilage repair and extracellular matrix technologies programs, Synthes' success in selling the Company's extracellular matrix products, the completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products and competition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

SOURCE Kensey Nash Corporation


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Announces $25 Million Stock Repurchase Program
3. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
6. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
9. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
10. Kensey Nash Reports Third Quarter Record Revenue and Sales
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 17, 2017 , ... Recently, patients and staff from A ... other volunteers and organizations in support of the annual Binder Park Zoo Halloween celebration ... up in colorful costumes of all designs coming out to enjoy games, face painting, ...
(Date:1/16/2017)... ... ... Anybody who may be looking for a substance abuse rehabilitation program with ... a holistic treatment center for addiction located in Marne, MI. This video, which can ... and staff that visited the 2016 Recovery Palooza support event in nearby Grand Rapids. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company ... in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide BraunAbility ... accessible vehicles. With this new incentive plan, BraunAbility plans to continue their tradition ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... One thing ... only to treat, but to test for, as well. The money spent screening for ... year.(1) Doctors in the U.S. screen patients for cancer more than in any other ...
(Date:1/15/2017)... ... 15, 2017 , ... Going above and beyond the practical ... better communities around the world by offering the Gensuite team and their services ... team members to become involved in a cause that is bigger than themselves ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... TORONTO , Jan. 16, 2017 When synthetic ... to market their product as top-rate. They offered free samples, ... top-notch customer service. Soon, business was booming. ... often described as 100 times more powerful than morphine, has ... in last 2 years. One dealer,s recorded fentanyl ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 /PRNewswire/ ... Research, titled, "Vital Signs Monitoring Devices Market by Type and ... that the global vital signs monitoring devices market size was ... $5,491 million by 2022, growing at a CAGR of 5.8% ... was the leading regional market in global vital signs monitoring ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... & Its Derivatives Market by Product Type (Methyl, ... Personal Care, Foods & Beverages, Surface Coatings ... 2021", published by MarketsandMarkets, the market was ... and is projected to reach USD 6.41 ...
Breaking Medicine Technology: